<DOC>
	<DOCNO>NCT00458822</DOCNO>
	<brief_summary>The purpose study patient need treatment AL amyloidosis see well treatment IV melphalan work , clonal plasma cell still present 2 3 month melphalan treatment , see well treatment bortezomib dexamethasone work reduce rest clonal plasma cell disease .</brief_summary>
	<brief_title>Melphalan Autologous Stem Cell Transplant Followed By Bortezomib Dexamethasone Treating Patients With Previously Untreated Systemic Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm amyloidosis Diagnosed within past 12 month Clonal plasma cell disorder , demonstrate following : Presence Mprotein serum and/or urine immunofixation and/or serum free light chain assay Clonal population plasma cell bone marrow base kappa/lambda stain marrow biopsy Negative genetic test hereditary form amyloidosis No amyloidspecific syndrome ( e.g. , carpal tunnel syndrome skin purpura ) evidence disease Vascular amyloidosis bone marrow biopsy specimen plasmacytoma indicative systemic amyloidosis No advance cardiac amyloidosis Must symptomatic involvement 2 follow visceral organ system : Kidneys Liver/gastrointestinal Peripheral/autonomic nervous system Heart No persistent pleural effusion No clinically overt multiple myeloma &gt; 30 % plasma cell bone marrow lytic bone lesion Able undergo autologous stem cell transplantation PATIENT CHARACTERISTICS : SWOG performance status 03 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Bilirubin &lt; 2.0 mg/dL Creatinine clearance &lt; 51 mL/min allow LVEF &gt; 45 % echocardiogram No New York Heart Association class IIIIV congestive heart failure No history cardiac syncope No recurrent symptomatic arrhythmia No oxygendependent restrictive cardiomyopathy No myocardial infarction within past 6 month Pulmonary diffusion capacity &gt; 50 % predict pulmonary function test No uncontrolled infection No active malignancy , except follow : Adequately treat basal cell squamous cell skin cancer In situ cervical cancer Adequately treat stage I cancer patient currently complete remission Any cancer patient diseasefree 5 year No hypersensitivity bortezomib , boron , mannitol No HIV positivity No serious medical psychiatric illness would preclude study compliance PRIOR CONCURRENT THERAPY : At least 14 day since prior investigational drug No prior therapy monoclonal plasma disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>